Paclitaxel Injection IP

Get a Price/Quote

MOQ : 10 Units

Paclitaxel Injection IP Specification

Salt Composition
Paclitaxel

Indication
Anticancer, Breast cancer, Ovarian cancer, Non-small cell lung cancer

Dosage Form
Injection

Feature
Sterile, single-dose vial

Ingredients
Paclitaxel with excipients

Application
Intravenous infusion for cancer therapy

Physical Color/Texture
Clear, colorless to faint yellow solution

Fermentation Smell
Odorless

Storage Instructions
Store below 25C, protect from light

Shelf Life
24 months

Marketed By
Cipla

Strength
30 mg/5 ml

Packaging Type
Glass vial with carton box

Route of Administration
Intravenous

Prescription Required
Yes

Paclitaxel Injection IP Trade Information

Minimum Order Quantity
10 Units

Payment Terms
Cash in Advance (CID)

Supply Ability
1000 Units Per Month

Delivery Time
5-7 Days

Main Domestic Market
All India

Paclitaxel Injection IP About

Paclitaxel Injection IP 30 mg/5 ml, expertly marketed by Cipla, is a cost-effective and exclusive solution for oncological care. Delivered in a sterile single-dose glass vial, this phenomenal product is tailor-made for intravenous administration. It is a dominant choice for treating breast, ovarian, and non-small cell lung cancers, offering heroic support to patients worldwide. Carefully formulated with Paclitaxel and excipients, each vial is odorless, clear to faint yellow, and must be stored below 25C. Suitable for procurement by exporters, suppliers, and traders across India, this injection signifies superior quality and reliability in cancer therapy.

Comprehensive Clinical Use & Advantages

Paclitaxel Injection IP is utilized intravenously, making it ideal for precise cancer therapy. Widely used in hospitals and clinics for managing breast, ovarian, and non-small cell lung cancer, its dominant efficacy is well-recognized among oncologists. The advantage of its sterile, single-use vial guarantees safety and minimizes contamination risks, making it a phenomenal choice for commercial medical procurement.

Sample Availability, Payment Terms & Sample Policy Details

Prospective buyers can request samples of Paclitaxel Injection IP. A modest proposal amount or outlay may be needed for handover of samples, depending on supplier policy. Payment terms are flexible, tailored to the specific exporter or trader's standard practice. The sample policy is clear, facilitating potential commercial partnerships through an efficient and transparent process.

FAQ's of Paclitaxel Injection IP:

Q: How should Paclitaxel Injection IP be stored to maintain its efficacy?

A: Paclitaxel Injection IP must be stored below 25C and protected from light. Proper storage ensures the medication remains effective up to its 24-month shelf life.

Q: What is the process for procuring Paclitaxel Injection IP for commercial use?

A: To procure Paclitaxel Injection IP, interested exporters, suppliers, or traders can contact authorized distributors or the manufacturer, Cipla. Procedures typically involve submitting a proposal and negotiating terms for bulk orders.

Q: Where can Paclitaxel Injection IP be administered and for which types of cancer?

A: This injection is administered intravenously in clinical or hospital settings under medical supervision, specifically for breast cancer, ovarian cancer, and non-small cell lung cancer.

Q: What are the physical characteristics of Paclitaxel Injection IP?

A: The injection is a clear, colorless to faint yellow solution, provided in a sterile glass vial. It is odorless and intended for single-dose use.

Q: What benefits does Paclitaxel Injection IP offer over other formulations?

A: This dominant injection ensures safety through sterile, single-use vials and offers cost-effective, heroic cancer therapy supported by reliable quality control from Cipla.

Tell us about your requirement